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Abstract The European Paediatric Regulation mandated the
European Commission to fund research on off-patent medi-
cines with demonstrated therapeutic interest for children.
Responding to this mandate, five FP7 project calls were
launched and 20 projects were granted. This paper aims to
detail the funded projects and their preliminary results. Pub-
licly available sources have been consulted and a descriptive
analysis has been performed. Twenty Research Consortia
including 246 partners in 29 European and non-European
countries were created (involving 129 universities or public-
funded research organisations, 51 private companies with 40
SMEs, 7 patient associations). The funded projects investigate
24 medicines, covering 10 therapeutic areas in all paediatric
age groups. In response to the Paediatric Regulation and to
apply for a Paediatric Use Marketing Authorisation, 15 Pae-
diatric Investigation Plans have been granted by the EMA-
Paediatric Committee, including 71 studies of whom 29 pae-
diatric clinical trials, leading to a total of 7,300 children to be
recruited in more than 380 investigational centres.
Conclusion: Notwithstanding the EU contribution for each
study is lower than similar publicly funded projects, and also
considering the complexity of paediatric research, these pro-
jects are performing high-quality research and are progressing
towards the increase of new paediatric medicines on the
Communicated by Beat Steinmann
L. Ruggieri (*) :V. Giannuzzi :A. Ceci
Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus, Via
Abate Eustasio 30, 70010 Valenzano, BA, Italy
e-mail: lr@benzifoundation.org
P. Baiardi : F. Bonifazi :D. Bonifazi :M. Felisi :A. Ceci
Consorzio per Valutazioni Biologiche e Farmacologiche, Via L. Porta
14, 27100 Pavia, Italy
E. H. Davies : C. Giaquinto
Paediatric European Network for Treatment of AIDS, Via Giustiniani
3, 35128 Padova, Italy
C. Giaquinto
Department of Paediatrics, Azienda Ospedaliera di Padova (AOPD),
Via Giustiniani 1, 35128 Padova, Italy
C. Chiron : E. Jacqz-Aigrain
Institut National de la Sante et de la Recherche Medicale, 101 Rue de
Tolbiac, 75654 Paris, France
R. Pressler
Great Ormond Street Hospital for Children NHS Foundation Trust,
Great Ormond Street, London WC1N 3JH, UK
H. Rabe
Brighton and Sussex University Hospitals, Brighton, UK
M. J. Whitaker
The University of Sheffield, Barber House 387 Glossop Road,
Sheffield S10 2HQ, UK
A. Neubert
Department of Paediatric and Adolescent Medicine, University
Hospital Erlangen, Loschgestrasse 15, 91054 Erlangen, Germany
I. Eichler
European Network of Paediatric Research at the European Medicine
Agency, 30 Churchill Place Canary Wharf, London E14 5EU, UK
M. A. Turner
Department of Women’s and Children’s Health, Institute of
Translational Medicine, Liverpool Women’s NHS Foundation Trust,
University of Liverpool, Crown Street, Liverpool L8 7SS, UK
Eur J Pediatr
DOI 10.1007/s00431-014-2398-z
market. Private–public partnerships have been effectively im-
plemented, providing a good example for future collaborative
actions. Since these projects cover a limited number of off-
patent drugs and many unmet therapeutic needs in paediatrics
remain, it is crucial foreseeing new similar initiatives in forth-
coming European funding programmes.
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PDCO Paediatric Committee
PIP Paediatric Investigation Plan
PK Pharmacokinetics
PUMA Paediatric Use Marketing Authorisation
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Introduction
In Europe, fewer than 30 % of marketed drugs include results
from paediatric clinical trials and other information on paedi-
atric use in their documentation (Summary of Product Char-
acteristics, SPC or Product Leaflet, equivalent to US label) [3].
The lack of paediatric medicines is particularly concerning for
neonates and in serious and life threatening diseases [4, 6].
The main consequence of this situation is the widespread
off-label use in paediatrics, especially in the case of old drugs
that have never received a paediatric authorisation. The pae-
diatric ‘off-label use’ specifically refers to ‘all paediatric uses
of a marketed drug not detailed in the SPC’ [18]. The off-label
paediatric use in Europe accounts for 45–60 % of the total
number of prescriptions with rates of up to 90 % in the
premature and term neonates, infants and paediatric patients
admitted to intensive care units [11].
Moreover, it is well known that studies and trials involving
children are affected by many methodological [1] and ethical
concerns [17] as well as by economic barriers [13] resulting in
difficulties to perform high-quality paediatric studies [5, 22],
compliant with the existing guidelines and recommendations
for high-quality paediatric studies [10, 14]. One barrier is the
lack of incentives for companies to develop medicines that
contain an off-patent active pharmaceutical ingredient. The
entry into force of the Paediatric Regulation in 2007 (Europe-
an Commission (EC) 1901/2006 as amended [8]) gave an
important contribution to reduce the above-mentioned barriers
and to support the development of medicines for children.
Among other provisions, the Paediatric Regulation introduced
a specific measure to favour work on off-patent medicines, the
Paediatric Use Marketing Authorisation (the so called PU-
MA). This grants a 10-year period of data exclusivity in case
of paediatric development of adult medicines that are not
protected by a patent or supplementary protection certificate
(off-patent drugs). A PUMA application should include the
submission of paediatric data in accordance with an agreed
Paediatric Investigation Plan (PIP) [9]. According to Article
40 of the Regulation, the European Research Framework
Programmes should reserve funds to support PUMAs in case
of off-patent drugs recognised as of high therapeutic interest
for children and included in a ‘priority list’ (PL) adopted, on
annual basis, by the European Medicines Agency (EMA)
through its Paediatric Committee. In the last 6 years, such
EC funds have been delivered through the Seventh Frame-
work Programme for Research (FP7-FRP). In particular with
reference to HEALTH-(2007–2013) Programme area, five
calls for proposal have been released with reference to the
topic 4.2-1 ‘to develop off-patent medicinal products for the
paediatric population’.
These specific calls are characterized by the fact that
they should respond both to the criteria for scientific
excellence stated in the FP7 EC Programmes and meet
standards for high-quality paediatric research as pre-
sc r ibed by the Paedia t r i c Regula t ion ( tha t i s
implementing paediatric studies to be conducted accord-
ing to an agreed PIP). They should also stimulate re-
search capacity and support the broader EU commitment
to small-to-medium-sized enterprises (SMEs1).
This paper aims to describe the paediatric projects
funded in the framework of the Paediatric Regulation
and evaluate their capacity to improve public health by
meeting the policy drivers that justified the funding for
supporting research capacity, innovation from SMEs and
high-quality paediatric studies that contribute to the
development of medicines for children and progress
towards PUMAs.
1 The category of micro, small and medium-sized enterprises (SMEs) is
made up of enterprises which employ fewer than 250 persons (50 and 10
in case of small and micro, respectively) and which have an annual
turnover not exceeding 50 million euros, and/or an annual balance sheet
total not exceeding 43 million euros (Commission Recommendation of 6
May 2003 concerning the definition of micro, small and medium-sized
enterprises, notified under document number C(2003) 1422) (2003/361/
EC)
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Methodology
Data sources
To collect information on the FP7 Paediatric funded projects
(content and status), the following sources have been
consulted:
(a) Community Research and Development Information
Service (CORDIS) database, available from http://
cordis.europa.eu/home_en.html
(b) Project websites2
(c) EC-EMAwebsites: Priority list of off-patent medicines,
different versions developed from 2007 to 2013
(d) EMA: Published Paediatric Committee (PDCO) deci-
sions on Paediatric Investigation Plans (PIPs), available
from http://www.ema.europa.eu/ema/index.jsp?curl=
pages/medicines/landing/pip_search.jsp&mid=
WC0b01ac058001d129
(e) The European Clinical Trials Register, available from
https://www.clinicaltrialsregister.eu/ctr-search/search
(f) The global database of clinical trials ClinicalTrials.gov,
available from http://clinicaltrials.gov/
(g) Scientific publications, conference presentations and
meeting reports related to the projects, where available
(h) EuOrphan, a database of orphan drugs designed/
approved in Europe and in the USA [15]
Information collected
& Funded projects and economic information (the total costs
of the projects and the funds received by the European
Commission);
& General information on the Research Consortia
established in the framework of these projects;
& Information on the investigated active substance(s) or
medicinal products, indication(s) and therapeutic area(s);
& Information on the specific measures and requirements
included in the project:
– Obligation to submit a Paediatric Investigation Plan;
– Presence of studies to develop age-appropriate formula-
tions (new preparations of the drugs) or forms of medi-
cines (new dosages and strengths);
– Subgroups of paediatric population;
& Trials and other studies (number, type and study
characteristics).
Data were validated, and incomplete or inaccurate data
have been sought, by e-mail contacts with the coordinators
of the projects.
Results
Description of funded projects
Projects
According to the CORDIS database and other EC sources [7],
in the period of 2006–2012, five calls have been launched in
the context of the FP7 programme with reference to topic 4.2-
1 ‘to develop off-patent medicinal products for the paediatric
population’. Under the framework of these calls, a total of 76
proposals have been submitted and 20 have been funded with
a success rate of 26.3 %. This analysis describes the 20
projects, listed in Table 1, devoted to paediatric studies to
support a PUMA. The total amount awarded to these projects
is 98.6 million euros (see Table 1).
Active substances
The 20 approved projects are investigating a total of 24
active substances, 8 of which (methotrexate, 6-
mercaptopurine, ciprofloxacin, budesonide, doxorubicin,
deferiprone, hydrocortisone and clonidine) have been
granted a European Orphan Drug (OD) designation. In
fou r ca s e s (me t ho t r exa t e , 6 -me r cap topu r i n e ,
hydrocortisone and deferiprone) the orphan conditions
matches the Priority List indications (acute lymphoblas-
tic leukaemia for the first two, adrenal insufficiency and
sickle cell disease, respectively).
The substances are intended to treat a total of 22
paediatric indications in 10 therapeutic areas (Table 2).
The most represented area is ‘infection’ accounting for
four projects.
Research capacity
The 20 Research Consortia generated by the projects
encompass 246 European and non-European institutions.
The smallest Consortium includes four partners; the
biggest one includes 18 participant members (Table 1).
In addition, an average number of 6–8 investigational
centres are included as third parties in each project. A
total of 29 countries (22 European Member States and 7
non-European Member States) are involved with the
UK, France, Italy and Germany being the most fre-
quently represented, both in terms of number of partic-
ipants and number of projects (Fig. 1). Four projects
(HIP trial, DEEP, NEO-CIRC and GAPP) also include
2 Not all the project websites provide the same amount of information and
their update is not homogeneous
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non-EU countries in their partnership. France and Italy
together account for 50 % of coordinators (respectively,
six and four) followed by UK and Germany (three
projects each).
Most of the partners are universities and public-funded
national research centres or institutions, 51 are private
companies of which almost 40 are SMEs. Seven out of
20 project consortia (03K, DEEP, EPOC, TAIN, CloSed,
GAPP and NEO-CIRC) include a patient association,
while 9 out of 20 project consortia (NEuroSIS, EPOC,
DEEP, NeoMero, PERS, LENA, GAPP, NeoVanc,
CloSed) include a not-for-profit research organisation,
as member or coordinator.
Paediatric studies that contribute to the development
of medicines for children
New forms/formulations development
Eighty percent of the projects include studies to develop new
age-appropriate formulations or dosage form: ten oral new
formulations (six liquid, three tablets soluble or effervescent
and one granule), seven new intravenous formulations and
three intravenous dosage forms.
Subgroups of paediatric population involved in clinical trials
All paediatric subgroups are represented in the clinical
trials (Fig. 2). In particular, 17 out of 29 paediatric
clinical trials include preterm and/or term newborns.
Projects NeoOpioid, NEuroSIS, NEMO, TINN and
TINN2, HIP trial, NEO-CIRC and NeoVanc specifically
address neonatal condition and for this reason patients
to be enrolled in clinical trials are only preterm/term
newborns.
Number and type of studies
A total of 71 studies are to be completed by the end of the 20
projects. They include studies in healthy adult volunteers (3),
formulation development (20), clinical trials in children (29),
non-interventional studies (6), in silico modelling (10) and
non-clinical studies in animals (3).
Table 1 The 20 European-funded projects in the framework of FP7 and the related costs and funds
FP7 call and subprogramme area Acronym and start year Total project cost (€) EU funds (€)
FP7-HEALTH-2007-B HEALTH.2007.4.2-1 Loulla and Philla, 2008 4,244,817 3,316,415
NeoOpioid, 2008 2,881,489 2,299,164
03K, 2008 6,836,663 5,228,003
TINN, 2008 6,820,915 5,161,000
NEuroSIS, 2009 7,383,283 5,623,414
EPOC, 2009 2,575,591 1,997,862
HEALTH-2009-single-stage
HEALTH.2009.4.2-1
NEMO, 2009 7,590,402 5,800,000
NeoMero, 2010 7,734,006 5,900,000
PERS, 2010 7,360,763 5,600,000
HEALTH-2010-single-stage
HEALTH.2010.4.2-1
TINN2, 2011 6,540,008 5,000,000
HIP trial, 2010 7,303,559 5,662,043
DEEP, 2011 8,126,820 5,262,963
HEALTH-2011-single-stage
HEALTH-2011.4.2-1
NEO-CIRC, 2011 7,814,643 5,999,167
TAIN, 2011 5,595,432 4,203,282
KIEKIDS, 2011 2,776,525 2,157,071
FP7-HEALTH-2013-INNOVATION-1
HEALTH.2013.4.2-1
CloSed, 2013 7,378,566 5,997,404
GAPP, 2013 7,189,924 5,476,875
METFIZZ, 2013 8,624,558 5,999,962
LENA, 2013 7,702,256 5,999,991
NeoVanc, 2014 7,882,015 5,993,000
TINNTreat Infections InNeonates,NEuroSISNeonatal European Study of Inhaled Steroids,EPOC European Paediatric Oncology Off-PatentMedicines
Consortium, NEMO NEonatal seizures with Medication Off-patent, PERS Pediatric European Risperidone Studies, HIP Hypotension In the Preterm,
DEEP Deferiprone Evaluation In Paediatrics, NEO-CIRC NeoCirculation Project, TAIN Treatment of Adrenal Insufficiency in Neonates and Infants,
CloSed Clonidine for Sedation, GAPP GAbapentin in Paediatric Pain, LENA Labeling of Enalapril from Neonates up to Adolescents
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Table 2 Active substance(s), paediatric indication(s) and therapeutic area
Project Active substance(S) Therapeutic area Addressed paediatric indication(s) Addressed paediatric indication(s),
as indicated in the PIP
TINN Ciprofloxacina Infections Treatment of infections in preterm
and term newborns
–
Fluconazole –
TINN2 Azithromycin Treatment of infections in preterm
and term newborns
Prevention of bronchopulmonary
dysplasia
NeoMero Meropenem Treatment of late onset sepsis in
neonates and infants aged
<3 months
Treatment of bacterial meningitis in
neonates and infants aged <3 months
Treatment of bacterial sepsis in neonates
and infants below 3 months of age
NeoVanc Vancomycin Treatment of late onset bacterial sepsis
caused by vancomycin susceptible
bacteria in neonates and infants
aged under 3 months
Treatment of bacterial sepsis caused by
vancomycin susceptible bacteria in
neonates and infants aged under
3 months
NeoOpioid Morphine Pain Treatment of acute pain Treatment of acute pain, treatment of
moderate to severe prolonged pain.
Fentanyl Pre-medication before a painful medical
procedure
GAPP Gabapentin Treatment of chronic pain Treatment of chronic pain of neuropathic
origin
Loulla and
Philla
Methotrexatea Malignant
neoplasms
Treatment of acute
lymphoblastic leukaemia6-Mercaptopurinea
03K Cyclophosphamide Treatment of paediatric malignancies Treatment of paediatric malignant diseases
including haematological malignancies
as well as soft tissue sarcoma,
neuroblastoma and retinoblastoma.
Temozolomide
EPOC Doxorubicina Treatment of childhood cancer
HIP trial Dopamine Cardiology Management of hypotension
in preterm newborns
Treatment of hypotension in the extremely
low gestational age newborn.
Treatment of hypotension in children
NEO-CIRC Dobutamine Treatment of systemic hypotension
in infants
Treatment of neonatal circulatory failure
in the first 72 h after birth.
LENA Enalapril Cardiac failure in children
NEMO Bumetanide Neurology Treatment of neonatal seizures in
babies with hypoxic ischemic
encephalopathy
KIEKIDS Ethosuximide Treatment of absence and myoclonic
epilepsy
TAIN Hydrocortisonea Endocrinology Treatment of adrenal insufficiency in
neonates and infants
METFIZZ Metformin Treatment of polycystic ovary syndrome Treatment of polycystic ovary syndrome
as adjunct to diet and exercise in
adolescent girls to improve menstrual
regularity and insulin resistance.
CloSed Clonidinea Intensive care/
anaesthesiology
Sedation in intensive care Sedation in intensive care
DEEP Deferipronea Haematology Treatment of chronic iron overload Treatment of iron overload in paediatric
patients affected by haemoglobinopathies
requiring chronic transfusion and iron
chelation.
PERS Risperidone Child and adolescent
psychiatry
Treatment of conduct disorder
Treatment of schizophrenia
Treatment of conduct disorder in children
and adolescents with average IQ
NEuroSIS Budesonidea Respiratory and
cardiovascular disorders
Prevention of bronchopulmonary
dysplasia
Prevention of bronchopulmonary dysplasia
(BPD) in preterm newborn infants.
a Received and Orphan Designation
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Two out of three studies planned in healthy adult
volunteers were PK, dose ranging and safety and one
was a PK study. On a total of 29 paediatric trials, 16
were randomised controlled, eight on clinical pharmacol-
ogy (PK/pharmacodynamics (PD)/dose finding), 9 non-
randomised efficacy and/or safety and 12 were PK/PD/
efficacy/safety. The estimated enrolment for all projects
is 7,300 children. A pharmacogenetic sub-study is fore-
seen in 13 clinical trials (Table 3). Almost all trials are
multicentre, involving 387 investigational sites, both in
European and non-European countries. Thirteen of the
paediatric trials are registered on the European Clinical
Trials Database (EudraCT).
Start of the studies and patients’ enrolment
Enrolment of participants has been evaluated in 15 of
20 projects, corresponding to 23 clinical trials (5 pro-
jects, receiving approval less than a year before the
survey, have been excluded from this analysis). At the
time of this review (July 2014), a total of 1,400 paedi-
atric patients (equal to 22.4 % of the estimated enrol-
ment for all 15 projects) have been included in trials.
This relates to five completed and eight ongoing trials.
Ten additional trials have concluded the approval pro-
cedures and are in the process of opening.
Support for SMEs
The partnership includes 51 private companies of which
13 are pharmaceutical companies and at least 40 meet
the definition of an SME according to the information
available to us. The projects are mainly coordinated by
universities or other public Institutions while companies
and not-for-profit research organisations are involved as
coordinators in two and four projects, respectively.
There are a significant number of private–public part-
nerships which would not have happened in the absence
of pump-priming funding.
Paediatric Investigation Plans
Fifteen approved PIPs referring to 14 projects are avail-
able, while two projects (TINN and LENA) have sub-
mitted a PIP application but not yet received an ap-
proved plan. As indicated in Fig. 3, no PIP has been
completed so far, and the completion date of the paedi-
atric developmental plan ranges from January 2015 to
end of 2018. No deferrals are foreseen in the plans.
During the PIP approval process, some changes in the
projects have been performed on PDCO request. These
changes have included new measures and patient popu-
lations, additional trials or studies, sample size revision,
modified statistical plan, and, more frequently, addition-
al or modified paediatric indications (Table 2). These
changes were mainly prompted by valuable scientific or
regulatory concerns and were accordingly integrated in
the projects. However, the need to come back for ap-
proval to the EC also influenced the timing and the
complexity of the projects performance. In addition,
even if new measures were requested by the PDCO,
no additional funds were made available by the funding
authority.
Progress towards PUMAs
PUMA applications require a PIP to be agreed, completion of
all measures according to the agreed plan and confirmation of
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compliance with the agreed PIP. According the timelines of
the FP7 projects, all of these steps should be completed within
5 years. While some projects may need extension, all of the
studies will be conducted in this short period. This is different
from the approach taken by many commercially funded PIPs.
According to the 5-year report on the impact of the Paediatric
Regulation drafted in 2012 by the EMA-PDCO [13], the
number of PIPs in which studies are deferred is very high
with 44 % of the approved PIPs not progressing as planned
[12].
Discussion and conclusions
Data collected and described provide evidence on how
these 20 FP7 approved project are contributing to the
success of the Paediatric Regulation which entered into
force in 2007 and aimed to overcome the existing meth-
odological and ethical issues affecting research in the
paediatric population.
Although many of the projects are still ongoing,
these results allow us to discuss the many positive
achievements obtained until now. Thanks to Article 40
of the Paediatric Regulation mandate, significant funds
to support drug development in children have been
provided. The FP7 paediatric projects have received a
total of 98.6 million euros (representing 15 % of all the
EC investments for research projects related to child
health in the considered time period) [7] to conduct a
total of 71 paediatric studies including 32 clinical trials,
corresponding to an average of only 1.4 million euros
for each study or trial. This average value does not
differ from similar projects funded in the FP7 [7] or
other projects, such as Innovative Medicines Initiative
(IMI) [16]).
However, the funding scheme of the described projects,
devoted to cover the development of drugs in order to put
them on the market, is a novelty for Europe considering
that before FP7, regulatory clinical trials were not included
in the projects funded by the commission. However, it
seems that the paediatric consortia generated by the FP7
paediatric projects are conducting these studies and trials
using a limited amount of money in comparison with the
recognised cost of paediatric trials in an approved PIP
which is estimated to be three to four times higher [2,
21]. In addition, in a very similar programme set up in
the USA, the Paediatric Trials Network has received US$95
million to support 16 paediatric clinical trials, correspond-
ing to 4.3 million euros for each trial [19]. Although it is
difficult to compare the costs of conducting clinical studies
Fig. 2 Details of paediatric age subgroups included in the clinical trials for each project
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in the USA and in Europe, since the payment system for
investigators and researchers is different, it seems that the
research consortia involved in these projects are able to
manage good clinical trials with a reduced amount of
resources. If this is the case, it suggests that this funding
stream has unlocked a great deal of enthusiasm among
child health professionals, who are also contributing to
the projects with their time and other resources, while
providing enough money to encourage institutions and
SMEs to participate.
A very large scientific community (246 partners or-
ganisations and hundreds recruiting centres including
academic, research organisations and public hospitals)
covering EU and non-EU countries has been mobilised.
Recent literature data demonstrated a very low involve-
ment of researchers from academic or public research
institutions in paediatric research in Europe compared
with the USA [2]. The paediatric consortia born within
these projects represent a critical mass of competencies
that is also attracting public and private companies,
Table 3 Paediatric clinical trials and pharmacogenetics
Trial type Investigational medicinal
product
Study design Pharmacogenetics
PK/PD/dose-finding Bumetanide – –
Deferiprone – –
Dobutamine – –
Doxorubicin – Analysis of polymorphisms in genes
coding for the enzymes involved
in the transport and metabolism
Enalapril – Not available
Fentanyl – Pharmacogenetic study
Morphine – Pharmacogenetic study
Fluconazole – Pharmacogenetic study
Efficacy and/
or safety
Azithromicin Randomised placebo-controlled Pharmacogenetic study
Bumetanide Randomised placebo-controlled –
Dobutamine Double-blind randomised placebo-controlled Pharmacogenetic study
Dopamine Double-blind randomised placebo-controlled Analysis of the genes coding for the
transport and metabolism metabolizing
enzymes to develop a pharmacogenetic assay
Risperidone Double-blind randomised placebo-controlled –
Risperidone Double-blind randomised placebo-controlled Analysis of genetic polymorphisms
associated with symptoms related
to risperidone use
Metformin Double-blind randomised placebo-controlled –
Meropenem Open-label randomised active-controlled Identification of genetic markers that
may affect response to therapy
Deferiprone Open-label randomised active-controlled –
PK/PD/efficacy/
safety
Ciprofloxacine Open-label non-controlled Pharmacogenetic study
Dobutamine Open-label non-controlled –
Ethosuximide Open-label non-controlled –
Hydrocortisone Open-label non-controlled –
Meropenem Open-label non-controlled –
Budesonide Double-blind randomised placebo-controlled Pharmacogenetics of steroids
Gabapentin + morphine Double-blind randomised placebo-controlled –
6-Mercaptopurine Open-label randomised active-controlled Pharmacogenetic analysis as primary
endpoint of the CT
Cyclophosphamide Open-label randomised active-controlled Not available
Vancomycin Randomised active-controlled Pharmacogenetic biomarkers for treatment
monitoring
Clonidine Double-blind randomised active-controlled –
Gabapentin Double-blind randomised active-controlled –
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scientific societies and patients’ organisations. The ef-
fect of this networking action is crucial and destined to
last well beyond the end of the single research project.
At present, each consortium has a very high risk to
disintegrate at the end of the funding period. Thus,
there is a need to sustain this capacity. The role of
SMEs is striking and it is important that these and other
SMEs are not discouraged from contributing to this type
of work in future.
Eighty percent of the projects are developing new formu-
lations and dosage forms of medicines specifically for the
paediatric population. Age-appropriate formulations are an
urgent need [20]. The 5-year report drafted in 2012 by the
EMA-PDCO states that, although for authorised medicines,
26 new pharmaceutical forms were authorised for paediatric
use since the entry of the Paediatric Regulation, a lack of age-
appropriate formulations, in terms of safety of excipients,
palatability, acceptability, dosing flexibility, accuracy and
practical handling still exist [13].
The rich variety of study designs which have been adopted
following peer review and detailed scrutiny by EMA suggests
that high-quality studies have been tailored to the specific
situations. In addition pharmacogenetic substudies intended
to correlate the different pharmacological response to genetic
variability are strongly represented as a fundamental step in
the way to identify rational drug dosing.
The 29 ongoing paediatric trials represent a valuable per-
centage (14 %) of all the paediatric trials included in the
EudraCT database with reference to an approved PIP, and
the number of patients recruited or to be recruited (around
7,300 representing 23 % of all the paediatric patients included
in clinical trials in Europe from 2007 to 2011 [13]) is highly
remarkable. Furthermore, to date, 22 % of the projected en-
rolment for these trials is complete even though the majority
of trials are yet to open. This is in contrast with the reported
low recruitment capacity and difficulties with the conduct of
paediatric trials [21, 22] and again demonstrates the relevance
of the FP7 projects in the contest of paediatric research. The
inclusion of neonates and younger paediatric subgroups is
particularly important, and in contrast with the historic defi-
ciency of medicine development in these populations. Finally,
the strong engagement of commercial partners and sponsors
should stimulate a critical appraisal of the PUMA concept.
Commercial entities are clearly enthusiastic about developing
medicines for children, but so far, only 2 PUMAs have been
approved out of more than 1,000 PIPs. The PUMA is not an
attractive incentive for companies [13], and in particular,
SMEs, to facilitate the development and repurposing of
marketed drugs for children. Developing a more appropriate
incentive is of fundamental relevance for the future, since
companies should be encouraged to invest in this sector. The
fee reduction policy for SMEs that has been established and
periodically renewed by the EMA, a larger use of free charge
regulatory consultation for SME, the availability of large
paediatric research infrastructures like what provided by the
EnpREMA can be considered as promising instruments to
increase the commitment of companies in this field.
To complete the picture provided by this analysis, some
critical aspects should be discussed. As underlined in the
introduction, the challenging issue for FP7 paediatric projects
is to respond to different requirements imposed by the Re-
search Programmes framework (deadline, limited resources,
scientific publications, etc.) and by the Paediatric Regulation
(PIP should be agreed, all the paediatric population should be
covered, unmet paediatric needs prevail over scientific inter-
est). The recommendations of the PDCO mean that relevant
differences can be created from the original project mainly in
term of (a) number of studies, (b) patients populations, (c)
paediatric indications and (d) studies design. For these rea-
sons, the implementation of PIPs has represented a critical
point in the framework of these projects causing prolongation
of the contractual procedures with the EC and often, delays in
the start of the studies.
A further potential weakness is represented by time and
trials management. As a result of the complexity of the ad-
ministrative and ethic procedures for trial approval, each
consortium has experienced the need to address specific reg-
ulatory and organisation activities that are usually outside the
fields of competence of the academic and not-for-profit re-
search groups. These activities include structured interopera-
bility among participants, standard operating procedures to be
adopted, to adhere to GCP and the requirements of trials
included in the applications for MA, ethical, administrative
and contractual requirements, etc.
Our results demonstrate that the majority of these chal-
lenges can be positively addressed and mainly resolved. A
valid regulatory expertise seems to have been incorporated in
many FP7 Paediatric Consortia that demonstrate the ability to
mobilise a large scientific and clinical community. These
private–public partnerships have devised clinical develop-
ment plans and have conducted paediatric clinical studies that
Fig. 3 Details on the completion date of the agreed PIP
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are acceptable to regulators and Ethics Committees. However,
further efforts are needed, such as high level educational
activities addressed to researchers and health professionals
involved in paediatric trials and an increased active collabo-
ration and resources exchange among academics, health care
professionals, regulatory bodies and industry. Our expectation
is that the Global Research in Paediatric (GRiP3),
implementing an infrastructure matrix to stimulate and facil-
itate the development and safe use of medicines in children
will provide a fundamental contribution in both these fields.
In conclusion, despite the reported difficulties and limita-
tions, these projects are successful in many ways, are meeting
the expectations of the European Commission and of the
evolving Paediatric Regulation aimed to improve the health
of children and led to functional paediatric drug development
pathways [23]. However, much work remains to be done to
make the most of the opportunities provided by these common
regulatory perspectives. Therefore, new initiatives are re-
quired that will consolidate the experience and communities
which have been developed by the FP7 projects. On one hand,
expanded funding programmes for paediatric medicines
should be made available in “Horizon 2020” or other EC
Research Funds, including the Innovative Medicine Initiative
(IMI) project, to meet the mandate from the European Parlia-
ment provided by Paediatric Regulation Article 40. On the
other hand, it could be important that government and regu-
latory institutions provide the right framework allowing com-
panies to be rewarded for their investments in paediatric
clinical research.
Progress to date suggests that further work to develop
medicines for children through EC-funded private–public
partnerships will be productive, will provide value for money
and will continue to improve public health.
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